Tumour mutation burden (TMB) ranged from 0 to 35.48 mutations per Mb; it increased with higher BCLC stages but decreased in stage D. The top five mutated genes were <i>TP53</i> (39.8%), <i>CTNNB1</i> (15.7%), <i>LRP1B</i> (12.0%), <i>ARID1A</i> (10.8%) and <i>FAT3</i> (9.0%). Here, ARID1A is linked to neoplasm.